Li Bian

Dr. Li Bian


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2021 in Oncology Letters
Verified
Journal Article
Open access
PDF file
XRXiaobin Ren
Xiaobin Ren
LLLei Li
Lei Li
JWJianhua Wu
Jianhua Wu
KLKen Lin
Ken Lin
YHyongwen he
yongwen he
LBLi Bian
Li Bian
The most abundant cells in the tumor microenvironment are cancer‑associated fibroblasts (CAFs). They play an important role in oral squamous cell carcinoma (OSCC) angiogenesis, invasion and metastasis. Platelet‑derived growth factor (PDGF)‑BB has an obvious regulating effect on the formation of CAFs through binding to PDGF receptor (PDGFR)‑β, but the role of long non‑coding (lnc)RNA in PDGF‑BB‑induced transformation of fibroblasts into CAFs remains poorly understood. Using an lncRNA ChIP, 370 lncRNA transcripts were identified to be significantly and differentially expressed between fibroblasts and PDGF‑BB‑induced fibroblasts, including 240 upregulated lncRNAs and 130 downregulated lncRNAs, indicating that lncRNAs are involved in the regulation of the transformation of CAFs. Previous studies have shown that the nuclear factor (NF)‑κB signaling pathway plays an important role in the activation of CAFs. Dual‑luciferase reporter assay and co‑immunoprecipitation were conducted to confirm that the leucine‑rich adaptor protein 1‑like (LURAP1L), which is the target of lncRNA LURAP1L antisense RNA 1 (LURAP1L‑AS1) had a positive regulatory effect on I‑κB kinase (IKK)/NF‑κB signaling. Therefore, LURAP1L‑AS1 was selected and PDGF‑BB was demonstrated to upregulate the expression of LURAP1L‑AS1 and LURAP1L, which was reversed by a PDGFR‑β inhibitor. Subsequently, knocking down LURAP1L‑AS1 suppressed the expression of PDGF‑BB‑induced fibroblast activation marker protein α‑smooth muscle actin, fibroblast activation protein‑α, PDGFR‑β and phosphorylated (p)‑PDGFR‑β. IKKα, p‑IĸB and p‑NF‑κB were downregulated by the knockdown of LURAP1L‑AS1 and upregulated by overexpression of LURAP1L‑AS1. The present study indicates that LURAP1L‑AS1/LURAP1L/IKK/IĸB/NF‑κB plays an important regulatory role in PDGF‑BB‑induced fibroblast activation and may become a potential target for the treatment of OSCC.

20 December 2017 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
ZLZiliang Li
Ziliang Li
JLJianqi Liu
Jianqi Liu
LLLei Li
Lei Li
SSShuai Shao
Shuai Shao
JWJianhua Wu
Jianhua Wu
YHyongwen he
yongwen he
The present study aimed to assess the induction of epithelial-mesenchymal transition (EMT), invasion, and metastasis by the chemokine CXCL9/receptor CXCR3 axis in tongue squamous cell carcinoma (TSCC), unveiling the underlying mechanisms and providing new insights into the prevention and treatment of oral cancer metastasis. The expression levels of CXCL9 and CXCR3 in TSCC tissue specimens were determined by immunohistochemistry, assessing differences between samples with cervical lymph node metastasis and those without. Moreover, protein expression or activity in the TSCC Cal-27 cell line was controlled by neutralizing antibodies, gene transfection, or knock-out. Then, alterations of cell proliferation, migration, invasion, and the cytoskeleton were analyzed by CCK-8, cell scratch, Transwell, and cyto-skeleton staining assays, respectively. Alterations of EMT markers (E-cadherin and vimentin) in Cal-27 cells were detected by immunofluorescence and western blotting. In addition, western blotting was utilized to detect protein expression levels of Akt2, p-Akt2, eIF4E and p-eIF4E, and to explore the regulatory roles and mechanisms of the CXCL9/CXCR3 axis in invasion and metastasis. Significantly increased expression levels of CXCL9 and CXCR3 were detected in tissue specimens with lymph node metastasis compared with those without (P<0.01). Overexpression of CXCL9/CXCR3 in Cal-27 cells resulted in cytoskeleton alterations, decreased E-cadherin expression, increased vimentin levels, enhanced migration and invasion (P<0.05), and increased phosphorylated Akt2 and eIF4E levels (P<0.05). These results revealed that in TSCC, the CXCL9/CXCR3 axis could activate the Akt signaling pathway, with EMT and cytoskeleton rearrangement, promoting invasion and metastasis.

23 July 2014 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
YYYing Yang
Ying Yang
YWYanmei Wang
Yanmei Wang
JHJinsong He
Jinsong He
GPGuoqing Pan
Guoqing Pan
XTXiaoyu Tuo
Xiaoyu Tuo
LBLi Bian
Li Bian
Malignant adenomyoepithelioma and adenoid cystic carcinoma are both rare malignant epithelial-myoepithelial tumors of the breast. We report a very rare case with a malignant adenomyoepithelioma combining with adenoid cystic carcinoma in a single mass.

5 March 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AHAriel L. Hernandez
Ariel L. Hernandez
CYChristian D. Young
Christian D. Young
LBLi Bian
Li Bian
KWKelsey Weigel
Kelsey Weigel
KNKyle Nolan
Kyle Nolan
XWXiao-Jing Wang
Xiao-Jing Wang
Purpose: SMAD4 loss causes genomic instability and the initiation/progression of head and neck squamous cell carcinoma (HNSCC). Here, we study whether SMAD4 loss sensitizes HNSCCs to olaparib (PARP inhibitor) in combination with radiotherapy (RT).Experimental Design: We analyzed HNSCC The Cancer Genome Atlas data for SMAD4 expression in association with FANC/BRCA family gene expression. Human HNSCC cell lines were screened for sensitivity to olaparib. Isogenic HNSCC cell lines were generated to restore or reduce SMAD4 expression and treated with olaparib, radiation, or the combination. HNSCC pretreatment specimens from a phase I trial investigating olaparib were analyzed.Results: SMAD4 levels correlated with levels of FANC/BRCA genes in HNSCC. HNSCC cell lines with SMAD4 homozygous deletion were sensitive to olaparib. In vivo, olaparib or RT monotherapy reduced tumor volumes in SMAD4-mutant but not SMAD4-positive tumors. Olaparib with RT dual therapy sustained tumor volume reduction in SMAD4-deficient (mutant or knockdown) xenografts, which exhibited increased DNA damage and cell death compared with vehicle-treated tumors. In vitro, olaparib alone or in combination with radiation caused lower clonogenic survival, more DNA damage–associated cell death, and less proliferation in SMAD4-deficient cells than in SMAD4-positive (endogenous SMAD4 or transduced SMAD4) cells. Applicable to clinic, 5 out of 6 SMAD4-negative HNSCCs and 4 out of 8 SMAD4-positive HNSCCs responded to a standard treatment plus olaparib in a phase I clinical trial, and SMAD4 protein levels inversely correlated with DNA damage.Conclusions: SMAD4 levels are causal in determining sensitivity to PARP inhibition in combination with RT in HNSCCs.

1 January 2022 in INQUIRY: The Journal of Health Care Organization, Provision, and Financing
Verified
Journal Article
Open access
XLXuan Luo
Xuan Luo
JXJian Guo Xu
Jian Guo Xu
ZWZhiYuan Wang
ZhiYuan Wang
XWXiaoFang Wang
XiaoFang Wang
QZQianYing Zhu
QianYing Zhu
LBLi Bian
Li Bian
Objective: Lung adenocarcinoma (LUAD) is a common malignant tumor with a poor prognosis. The present study aimed to screen the key genes involved in LUAD development and prognosis. Methods: The transcriptome data for 515 LUAD and 347 normal samples were downloaded from The Cancer Genome Atlas and Genotype Tissue Expression databases. The weighted gene co-expression network and differentially expressed genes were used to identify the central regulatory genes for the development of LUAD. Univariate Cox, LASSO, and multivariate Cox regression analyses were utilized to identify prognosis-related genes. Results: The top 10 central regulatory genes of LUAD included IL6, PECAM1, CDH5, VWF, THBS1, CAV1, TEK, HGF, SPP1, and ENG. Genes that have an impact on survival included PECAM1, HGF, SPP1, and ENG. The favorable prognosis genes included KDF1, ZNF691, DNASE2B, and ELAPOR1, while unfavorable prognosis genes included RPL22, ENO1, PCSK9, SNX7, and LCE5A. The areas under the receiver operating characteristic curves of the risk score model in the training and testing datasets were .78 and .758, respectively. Conclusion: Bioinformatics methods were used to identify genes involved in the development and prognosis of LUAD, which will provide a basis for further research on the treatment and prognosis of LUAD.

27 July 2023 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
YWYanghao Wang
Yanghao Wang
GLGuoyu Li
Guoyu Li
ZWZhiYuan Wang
ZhiYuan Wang
WWWeizhou Wang
Weizhou Wang
XWXiaofang Wang
Xiaofang Wang
LBLi Bian
Li Bian
Laminin Subunit Beta 3 (LAMB3) is a transcription factor and participates in the coding of laminin. It plays an important role in cell proliferation, adhesion, and transfer by regulating various target genes and signaling pathways. However, the role of LAMB3 in human pan-cancer immunology and prognosis is still poorly understood. The TCGA, GTEx, CCLE, and HPA databases were utilized for the analysis of LAMB mRNA and protein expression. The expression of LAMB3 in various immune and molecular subtypes of human cancer was examined using the TISIDB database. The prognostic significance of LAMB3 in various cancers and clinical subtypes was investigated using Kaplan-Meier and Cox regression analysis. The relationship between LAMB3 expression, various immune cell infiltration, immune checkpoints, tumor mutational load, microsatellite instability, and DNA methylation was examined using the TCGA database. Clinical samples of four lung cancer cell lines and eight lung cancer cases were collected to confirm the expression of mRNA in lung cancer. In 17 cancers, the mRNA for LAMB3 is expressed differently and has good diagnostic and prognostic value in 22 cancers. Cox regression and Nomogram analysis show that LAMB3 is an independent risk factor for 15 cancers. LAMB3 is implicated in a variety of tumorigenesis and immune-related signaling pathways, according to GO, KEGG, and GSEA results. LAMB3 expression was associated with TMB in 33 cancer types and MSI in 32 cancer types, while in lung cancer LAMB3 expression was strongly associated with immune cell infiltration and negatively correlated with all seven methylated CpG islands. Cellular experiments demonstrated that LAMB3 promotes malignant behavior of tumor cells. Preliminary mechanistic exploration revealed its close association with PD-L1, CTLA4, cell stemness gene CD133 and β-catenin-related signaling pathways. Based on these findings, it appears that LAMB3 could be a potential therapeutic target for immunotherapy and tumor prognosis. Our findings reveal an important role for LAMB3 in different cancer types.